Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Glioblastoma, IDH-Wildtype: early-phase trial registry
4 of 5 indexed Recurrent Glioblastoma, IDH-Wildtype trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 4 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Recurrent Glioblastoma, IDH-Wildtype: 5 US clinical trials tracked, 4 recruiting.
Recurrent Glioblastoma, IDH-Wildtype is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Mayo Clinic, running 2 of these trials.
Enrollment posture brief
Registry condition recurrent-glioblastoma-idh-wildtype
OPEN 4 | RECR 80% | LATE 0 | EARLY 5 | RANK #3391 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Leukemia of Ambiguous Lineage (80% recruiting · 10 trials)
Recurrent Glioblastoma, IDH-Wildtype lists 4 open slots (80% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Glioblastoma, IDH-Wildtype on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Glioblastoma, IDH-Wildtype is recruiting above its size-band peers.
4 of 5 indexed trials (80%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Recurrent Glioblastoma, IDH-Wildtype research.
Mayo Clinic accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.
-
Most Recurrent Glioblastoma, IDH-Wildtype trials plan to enrol fewer than 100 people.
Median target enrolment is 30 among the 5 trials that report a genuine target (sentinel values excluded). 5 of those (100%) plan for fewer than 100 participants.
-
Recurrent Glioblastoma, IDH-Wildtype research is mostly interventional.
5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
Mayo Clinic
NCT05465954
D2C7-IT + 2141-V11 Combination Post-resection in rGBM
Darell Bigner
NCT06455605
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
National Cancer Institute (NCI)
NCT06860594
Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy
Mayo Clinic
NCT05789394
Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma
Northwestern University
NCT06410248
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Glioblastoma, IDH-Wildtype records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Glioblastoma, IDH-Wildtype trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Glioblastoma, IDH-Wildtype page
5 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Recurrent Glioblastoma, IDH-Wildtype trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Mayo Clinic sponsors the most Recurrent Glioblastoma, IDH-Wildtype trials on record, review their full trial history before evaluating a specific study. See Mayo Clinic's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Glioblastoma, IDH-Wildtype condition card totals 5 registered trials; most-linked intervention Biospecimen Collection; top US site state Illinois. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.